Linezolid
Zyvox (linezolid) is a small molecule pharmaceutical. Linezolid was first approved as Zyvox on 2000-04-18. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, soft tissue infections, and staphylococcal infections amongst others in the USA. It is known to target amine oxidase [flavin-containing] A and amine oxidase [flavin-containing] B.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Zyvox (generic drugs available since 2015-06-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Linezolid
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Hospira | N-206473 RX | 2015-06-18 | 1 products, RLD, RS |
ZYVOX | Mylan | N-021130 RX | 2000-04-18 | 1 products, RLD, RS |
ZYVOX | Mylan | N-021131 RX | 2000-04-18 | 2 products, RLD, RS |
ZYVOX | Mylan | N-021132 RX | 2000-04-18 | 1 products, RLD, RS |
Show 2 discontinued
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J2020 | Injection, linezolid, 200 mg |
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LINEZOLID |
INN | linezolid |
Description | Linezolid is an organofluorine compound that consists of 1,3-oxazolidin-2-one bearing an N-3-fluoro-4-(morpholin-4-yl)phenyl group as well as an acetamidomethyl group at position 5. A synthetic antibacterial agent that inhibits bacterial protein synthesis by binding to a site on 23S ribosomal RNA of the 50S subunit and prevents further formation of a functional 70S initiation complex. It has a role as an antibacterial drug and a protein synthesis inhibitor. It is an oxazolidinone, a member of morpholines, an organofluorine compound and a member of acetamides. |
Classification | Small molecule |
Drug class | oxazolidinone antibacterials |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1 |
Identifiers
PDB | — |
CAS-ID | 165800-03-3 |
RxCUI | 190376 |
ChEMBL ID | CHEMBL126 |
ChEBI ID | 63607 |
PubChem CID | 441401 |
DrugBank | DB00601 |
UNII ID | ISQ9I6J12J (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Zyvox - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 21,787 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,983 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more